Corbus Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Corbus Pharmaceuticals's estimated annual revenue is currently $4.8M per year.
- Corbus Pharmaceuticals received $27.2M in venture funding in March 2017.
- Corbus Pharmaceuticals's estimated revenue per employee is $107,111
- Corbus Pharmaceuticals's total funding is $196.9M.
Employee Data
- Corbus Pharmaceuticals has 45 Employees.
- Corbus Pharmaceuticals grew their employee count by -10% last year.
Corbus Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Information Officer | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Director, Investor Relations & Corporate Communications | Reveal Email/Phone |
4 | CEO & Director | Reveal Email/Phone |
5 | Human Resources Operations Manager | Reveal Email/Phone |
6 | Project Coordinator/Executive Administrative Assistant | Reveal Email/Phone |
Corbus Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $17.5M | 72 | -8% | N/A | N/A |
#2 | $323.6M | 338 | -6% | $1.2B | N/A |
#3 | $43.1M | 145 | 19% | N/A | N/A |
#4 | $23.8M | 88 | 9% | N/A | N/A |
#5 | $17.4M | 74 | -16% | $154.8M | N/A |
#6 | $4.8M | 45 | -10% | $196.9M | N/A |
#7 | $31.6M | 117 | 15% | N/A | N/A |
#8 | $25.4M | 94 | 7% | N/A | N/A |
#9 | $14.3M | 59 | -31% | N/A | N/A |
#10 | $17M | 70 | -17% | N/A | N/A |
What Is Corbus Pharmaceuticals?
Corbus Pharmaceuticals (NASDAQ: CRBP) is a Phase 3, clinical-stage pharmaceutical company focused on advancing the development and commercialization of novel therapies to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Corbus Pharma was named one of the Best Places To Work by Boston Business Journal in 2017. Our people are high-achievers, innovative, creative and, above all else, passionate about what we do in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus eythematosus.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$196.9M
Total Funding
45
Number of Employees
$4.8M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Corbus Pharmaceuticals News
Corbus Pharmaceuticals Holdings Inc. stock falls Friday, still outperforms market MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms market on strong trading day MarketWatch
Corbus Pharmaceuticals Holdings, Inc. Quarterly Update Conference Call and Webcast November 8, 2018 Operator: Greetings and welcome to the Corbus Pharmaceuticals Quarterly Update Conference Call and Webcast. At this time, all participants are on a listen only mode. A Question and Answer sessi ...
Corbus Pharmaceuticals Holdings Second Quarter Earnings Conference Call August 6, 2020 Page 1 of 14 Operator: Hello and welcome to the Corbus Pharmaceuticals Second Quarter August 6, 2020 Earnings Conference Call. As a reminder, all participants are in a listen-only mode. If anyone should re ...
Other Companies in Norwood
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 45 | 55% | N/A |
#2 | $11.9M | 45 | 7% | N/A |
#3 | $7.5M | 48 | 0% | N/A |
#4 | $3.5M | 49 | 29% | N/A |
#5 | $3.5M | 50 | 2% | N/A |
Corbus Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-04-29 | $6.3M | Undisclosed | Article | |
| 2014-06-04 | $10.3M | Undisclosed | Aegis Capital Corp | Article |
| 2014-12-12 | $12.7M | Undisclosed | Article | |
| 2016-06-13 | $14.9M | Undisclosed | Article | |
| 2017-03-01 | $27.2M | Undisclosed | Article |